Cancer of unknown primary (CUP) is defined as a heterogeneous group of tumours that present with metastasis, and in which attempts to identify the original site have failed. They differ from other primary tumours in their biological features and how they spread, which means that they can be considered a separate entity. There are several hypotheses regarding their origin, but the most plausible explanation for their aggressiveness and chemoresistance seems to involve chromosomal instability. Depending on the type of study done, CUP can account for 2–9% of all cancer patients, mostly 60–75 years old. This article reviews the main clinical, pathological, and molecular studies conducted to analyse and determine the origin of CUP. The main strategies for patient management and treatment, by both clinicians and pathologists, are also addressed.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Occult Primary (Cancer of Unknown Primary [CUP]) Version 1.2018–November 9, 2017. https://www.nccn.org/professionals/physician_gls/pdf/occult.pdf. Accessed 2 Jan 2018.
Greco FA, Hainsworth J. Cancer of unknown primary site. Cancer: principles and practice of oncology. Philadelphia: Lippincott Williams and Wilkins; 2011.
Delgado-Bolton RC, Fernández-Pérez C, González-Maté A, Carreras JL. Meta-analysis of the performance of 18F-FDG PET in primary tumor detection in unknown primary tumors. J Nucl Med. 2003;44:1301–14. PubMed
Moller AK, Loft A, Berthelsen AK, Pedersen KD, Graff J, Christensen CB, et al. A prospective comparison of 18F-FDG PET/CT and CT as diagnostic tools to identify the primary tumor site in patients with extracervical carcinoma of unknown primary site. Oncologist. 2012;17:1146–54. CrossRefPubMedPubMedCentral
Johnson DB, Dahlman KH, Knol J, Gilbert J, Puzanov I, Means-Powell J, et al. Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. Oncologist. 2014;19:616–22. CrossRefPubMedPubMedCentral
Rekhtman N, Brandt SM, Sigel CS, Friedlander MA, Riely GJ, Travis WD, et al. Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing. J Thorac Oncol. 2011;6:451–8. CrossRefPubMed
Fizazi K, Greco FA, Pavlidis N, Pentheroudakis G, ESMO Guidelines Working Group. Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22:vi64–8.
National Institute for Health and Clinical Excellence. Metastatic malignant disease of unknown primary origin in adults: diagnosis and management. Clinical guideline [CG104]. https://www.nice.org.uk/guidance/cg104. Accessed 2 Jan 2018.
Handorf CR, Kulkarni A, Grenert JP, Weiss LM, Rogers WM, Kim OS, et al. A multicenter study directly comparing the diagnostic accuracy of gene expression profiling and immunohistochemistry for primary site identification in metastatic tumors. Am J Surg Pathol. 2013;37:1067–75. CrossRefPubMedPubMedCentral
Hainsworth JD, Rubin MS, Spigel DR, Boccia RV, Raby S, Quinn R, et al. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute. J Clin Oncol. 2013;31:217–23. CrossRefPubMed
Le Tourneau C, Delord JP, Goncalves A, Gavoille C, Dubot C, Isambert N, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 2015;16:1324–34. CrossRefPubMed
Fehri R, Rifi H, Alboueiri A, Malouche D, Ayadi M, Rais H, et al. Carcinoma of unknown primary: retrospective study of 437 patients treated at Salah Azaiez Institute. Tunis Med. 2013;91:205–8. PubMed
Culine S, Lortholary A, Voigt JJ, Bugat R, Theodore C, Priou F, et al. Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study–trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). J Clin Oncol. 2003;21:3479–82. CrossRefPubMed
- 2018 consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the diagnosis and treatment of cancer of unknown primary
L. de la Cruz-Merino
- Springer International Publishing
- Clinical and Translational Oncology
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
Neu im Fachgebiet Onkologie
e.Med Kampagnen-Visual, Mail Icon II